3. For breast cancer cells resistant to doxorubicin/paclitaxel, silybin treatment sensitized the cells to chemotherapeutic medicines by blocking the key oncogenic pathways STAT3, AKT, and ERK. Here, AKT1 is linked to breast carcinoma.